IRON
HEALTHCAREDisc Medicine Inc
$68.65+1.06 (+1.57%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving IRON Today?
No stock-specific AI insight has been generated for IRON yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$40.00$99.50
$68.65
Fundamentals
Market Cap$2.6B
P/E Ratio—
EPS$-6.64
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume379K
Avg Volume (10D)—
Shares Outstanding38.2M
IRON News
28 articles- A Look At Disc Medicine (IRON) Valuation After Legal Probes And FDA Complete Response LetterYahoo Finance·May 6, 2026
- Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 5, 2026
- ROSEN, HIGHLY RANKED INVESTOR RIGHTS COUNSEL, Encourages ODDITY Tech Ltd. Investors With Losses in Excess of $100k to Secure Counsel Before Important Deadline in Securities Class Action– ODDGlobeNewswire Inc.·Apr 25, 2026
- IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsGlobeNewswire Inc.·Apr 25, 2026
- Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsightGlobeNewswire Inc.·Apr 22, 2026
- Disc Medicine Insider Sells $380K in Stock Amid 70% One-Year SurgeMotley Fool·Apr 21, 2026
- Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire Inc.·Apr 21, 2026
- IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsGlobeNewswire Inc.·Apr 19, 2026
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRONGlobeNewswire Inc.·Apr 7, 2026
- IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsGlobeNewswire Inc.·Mar 27, 2026
- Disc Medicine, Inc. Investigated by the Portnoy Law FirmGlobeNewswire Inc.·Mar 27, 2026
- Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic ProtoporphyriaYahoo Finance·Mar 26, 2026
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Disc Medicine, Inc. – IRONGlobeNewswire Inc.·Mar 24, 2026
- Evaluating Disc Medicine (IRON) After Recent Share Moves And Conflicting Valuation SignalsYahoo Finance·Mar 11, 2026
- What 3 recent FDA rejections reveal about shifts inside the agencyPharmavoice·Mar 4, 2026
- Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsightYahoo Finance·Mar 3, 2026
- Disc Medicine CFO Sells $720k Worth of Shares Amid FDA RejectionMotley Fool·Mar 1, 2026
- Disc Medicine (IRON) Is Up 8.6% After Wider 2025 Losses And New Shelf Registration - What's ChangedYahoo Finance·Feb 28, 2026
- Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Feb 26, 2026
- Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows ConvictionMotley Fool·Feb 25, 2026
- Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 MillionMotley Fool·Feb 25, 2026
- This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer EmergesMotley Fool·Feb 25, 2026
- Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 CatalystMotley Fool·Feb 25, 2026
- Disc Medicine to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 24, 2026
- Disc Medicine to Seek Traditional FDA Approval for Bitopertin After EPP CRL; APOLLO Data Due Q4Marketbeat·Feb 23, 2026
- Disc Medicine (IRON) Valuation Check After FDA Complete Response Letter On Lead Bitopertin ProgramYahoo Finance·Feb 19, 2026
- FDA accepts BMS protein degrader for review; Disc rare disease drug rejectedBiopharmadive·Feb 18, 2026
- Disc Medicine's Multiple Catalysts Provide Runway Despite Bitopertin Delay, Morgan Stanley SaysYahoo Finance·Feb 17, 2026
All 28 articles loaded
Price Data
Open$68.56
Previous Close$67.59
Day High$69.10
Day Low$67.48
52 Week High$99.50
52 Week Low$40.00
52-Week Range
$40.00$99.50
$68.65
Fundamentals
Market Cap$2.6B
P/E Ratio—
EPS$-6.64
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume379K
Avg Volume (10D)—
Shares Outstanding38.2M
About Disc Medicine Inc
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company is headquartered in Watertown, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—